Anna Kathy Aman

Array ( [id] => 18747057 [patent_doc_number] => 11806347 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-07 [patent_title] => Transmucosal methods for treating psychiatric and neurological conditions [patent_app_type] => utility [patent_app_number] => 17/338573 [patent_app_country] => US [patent_app_date] => 2021-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11218 [patent_no_of_claims] => 58 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17338573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19430907 [patent_doc_number] => 20240299405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => APPLICATION OF ATP POTASSIUM CHANNEL MODIFIER IN PREPARATION OF ANTI-DIABETIC NEPHROPATHY DRUG [patent_app_type] => utility [patent_app_number] => 18/013252 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6994 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18013252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18700014 [patent_doc_number] => 11786500 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => Glutaminase inhibitor therapy [patent_app_type] => utility [patent_app_number] => 17/327225 [patent_app_country] => US [patent_app_date] => 2021-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 53 [patent_no_of_words] => 35122 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 388 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17327225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17496531 [patent_doc_number] => 11285215 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-29 [patent_title] => Pharmaceutical compositions comprising meloxicam [patent_app_type] => utility [patent_app_number] => 17/325616 [patent_app_country] => US [patent_app_date] => 2021-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 33 [patent_no_of_words] => 23781 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17325616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17065785 [patent_doc_number] => 20210268000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => NEFOPAM DOSAGE FORMS AND METHODS OF TREATMENT [patent_app_type] => utility [patent_app_number] => 17/322098 [patent_app_country] => US [patent_app_date] => 2021-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18185 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17322098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17221741 [patent_doc_number] => 11174231 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-11-16 [patent_title] => Inhibitors of cysteine proteases and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/322221 [patent_app_country] => US [patent_app_date] => 2021-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 160235 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17322221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17472429 [patent_doc_number] => 20220079933 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-17 [patent_title] => CRENOLANIB FOR TREATING TRK KINASE ASSOCIATED PROLIFERATIVE DISORDERS [patent_app_type] => utility [patent_app_number] => 17/320350 [patent_app_country] => US [patent_app_date] => 2021-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8671 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320350 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17065032 [patent_doc_number] => 20210267247 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => NON-VASOCONSTRICTING ENERGY-PROMOTING COMPOSITIONS CONTAINING KETONE BODIES [patent_app_type] => utility [patent_app_number] => 17/320657 [patent_app_country] => US [patent_app_date] => 2021-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7030 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320657 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18544147 [patent_doc_number] => 11717478 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => Methods for improving vision [patent_app_type] => utility [patent_app_number] => 17/318562 [patent_app_country] => US [patent_app_date] => 2021-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2285 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17318562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17050609 [patent_doc_number] => 20210260043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => CARBOHYDRATE-BINDING SMALL MOLECULES WITH ANTIVIRAL ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/314560 [patent_app_country] => US [patent_app_date] => 2021-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23141 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17314560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18418508 [patent_doc_number] => 20230172966 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => COMPOSITION FOR THE PREVENTION AND TREATMENT OF FOLATE AND/OR VITAMIN B12 DEFICIENCY CONDITIONS, PARTICULARLY HYPERHOMOCYSTEINEMIA [patent_app_type] => utility [patent_app_number] => 17/997833 [patent_app_country] => US [patent_app_date] => 2021-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4954 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17554865 [patent_doc_number] => 11311522 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-04-26 [patent_title] => Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide [patent_app_type] => utility [patent_app_number] => 17/313750 [patent_app_country] => US [patent_app_date] => 2021-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 101 [patent_figures_cnt] => 116 [patent_no_of_words] => 78934 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17313750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17020853 [patent_doc_number] => 20210244724 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => NEW THERAPEUTICAL COMPOSITION CONTAINING APOMORPHINE AS ACTIVE INGREDIENT [patent_app_type] => utility [patent_app_number] => 17/245209 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4650 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17245209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20270700 [patent_doc_number] => 12440464 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-14 [patent_title] => Method for treating respiratory viral infections comprising administration of fatty acid compositions [patent_app_type] => utility [patent_app_number] => 17/997604 [patent_app_country] => US [patent_app_date] => 2021-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9415 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17050614 [patent_doc_number] => 20210260048 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => METHODS OF TREATMENT [patent_app_type] => utility [patent_app_number] => 17/244065 [patent_app_country] => US [patent_app_date] => 2021-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 111176 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17244065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17020878 [patent_doc_number] => 20210244749 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => DARUNAVIR FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/242218 [patent_app_country] => US [patent_app_date] => 2021-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5256 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17242218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17020814 [patent_doc_number] => 20210244685 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY [patent_app_type] => utility [patent_app_number] => 17/242075 [patent_app_country] => US [patent_app_date] => 2021-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5122 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17242075 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18443550 [patent_doc_number] => 11679101 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-20 [patent_title] => Anhydrous compositions of mTOR inhibitors and methods of use [patent_app_type] => utility [patent_app_number] => 17/224799 [patent_app_country] => US [patent_app_date] => 2021-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 12975 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17224799 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18590180 [patent_doc_number] => 11739060 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-29 [patent_title] => Crystalline 5-methoxy-n,n-diallyltryptamine compounds [patent_app_type] => utility [patent_app_number] => 17/995516 [patent_app_country] => US [patent_app_date] => 2021-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 7345 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995516 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17569866 [patent_doc_number] => 11318118 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-05-03 [patent_title] => Methods and compositions for treating SARS-CoV-2 infection using carboxyamidotriazole orotate [patent_app_type] => utility [patent_app_number] => 17/301493 [patent_app_country] => US [patent_app_date] => 2021-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 6367 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17301493 [rel_patent_id] =>[rel_patent_doc_number] =>)